Apollo closed a €3 billion structured equity transaction with Bayer on September 16, 2026, securing minority equity ownership in a newly formed subsidiary that houses the German healthcare conglomerate’s long-acting reversible contraceptives portfolio. KKR joined Apollo as a minority co-investor at closing, syndicate capital alongside Apollo-managed funds and affiliates through the High Grade Capital Solutions unit of Apollo. The transaction injects non-dilutive liquidity directly into Bayer without triggering a formal divestiture, allowing Bayer to retain majority voting control and complete operational governance over pharmaceutical manufacturing, clinical distribution, and sales operations.
The completed recapitalization demonstrates how multinational life sciences groups rely on bespoke private capital solutions rather than conventional corporate debt markets or discounted rights issues to satisfy looming balance sheet obligations. Facing elevated European refinancing rates, billions of euros in impending bond maturities, and litigation outlays originating from legacy glyphosate exposures in the United States, investment-grade corporations increasingly carved out mature revenue-generating drug franchises into ring-fenced entities. Apollo designed this structure to generate contracted asset-level cash distributions while enabling the corporate sponsor to maintain full consolidation of earnings on its corporate income statements.
Under the operating terms of the contract, Bayer transfers assets including its hormonal intrauterine system brand Mirena, Kyleena, Jaydess/Skyla, and the subdermal implant Jadelle into the new vehicle. This specific therapeutic cluster generated €1.37 billion in net revenue during the trailing twelve-month reporting period, expanding at an annual rate exceeding 12% on higher unit adoption across North America. That predictable, cash-flow-positive profile provided Apollo and KKR sufficient collateral coverage to fund €3 billion in equity while yielding Bayer direct cash reserves to meet debt maturities without equity dilution.
Corporate liquidity demands collide with debt maturities
Bayer executed the transaction to address distinct capital requirements outlined by Bayer Chief Financial Officer Judith Hartmann. Hartmann stated that the arrangement expands liquidity reserves as Bayer navigates debt refinancing timelines and cash outflows connected to United States legal dockets. Operating liabilities stemming from the 2018 Monsanto transaction continue to constrain corporate free cash flow, leaving Bayer seeking balance sheet relief that avoids equity dilution or fixed-coupon interest charges.
Rather than executing an outright asset disposal that would reduce recurring EBITDA, Bayer isolates a stable product set to attract patient alternative capital. The subsidiary remains fully integrated within the Bayer Pharmaceuticals Division, preserving client commercial relationships across hospitals, procurement networks, and pharmacy benefit administrators.
Structured terms and platform deployment mechanics
The transaction routes through the High Grade Capital Solutions business of Apollo, led by Apollo Partner Jamshid Ehsani. This division concentrates on structuring hybrid equity, investment grade credit, and asset-backed instruments for corporate borrowers that require customized terms unavailable in public debt syndications. KKR participated directly alongside Apollo, supplying equity capital to meet the €3 billion syndication target.
| Deal Term | Structured Detail |
|---|---|
| Total Capital Provided | €3.0 billion ($3.4 billion) |
| Lead Structuring Partner | Apollo (High Grade Capital Solutions) |
| Syndicate Co-Investor | KKR |
| Underlying Operating Assets | Long-acting reversible contraceptives (Mirena, Kyleena, Jaydess, Jadelle) |
| Governance & Ownership Split | Bayer holds majority equity and operating control; Apollo and KKR hold minority stake |
| Accounting Treatment | Fully consolidated in Bayer Group consolidated financial statements |
Financial advisors and legal counsel managed complex cross-border documentation to carve the commercial rights into the operating vehicle. Bayer retained BofA Securities and Deutsche Bank as financial advisors, with Linklaters LLP acting as legal advisor. Apollo engaged Centerview Partners as lead financial advisor, while Latham & Watkins LLP, Paul, Weiss, Rifkind, Wharton & Garrison LLP, and NautaDutilh N.V. provided legal counsel to the syndicate.
Corporate carve-outs replace standard high-yield debt
The Bayer transaction reflects a structural shift across European corporate balance sheets. Data compiled by Bain & Company indicates private equity exit strategies and corporate divestiture patterns shifted sharply toward structured carve-outs during the 2024 to 2026 cycle, driven by borrowing spreads that penalized corporate balance sheets carrying leverage ratios above three times EBITDA. Corporate finance teams frequently bypass public high-yield issuance in favor of high-grade private capital solutions that do not degrade credit ratings or dilute existing equity holders.
Apollo Partner Jamshid Ehsani confirmed that the agreement reflects a broader regional investment blueprint, with Apollo committing to deploy over $100 billion into corporate partnerships across Germany during the coming decade. Similar transactions in European telecommunications, utilities, and pharmaceutical manufacturing demonstrate that sponsors can achieve equity-like risk protections by underwriting specific corporate intellectual property rather than acquiring entire corporate parents.
Commercial fundamentals of the contraceptives portfolio
The underlying asset base holds commercial defensibility within international women’s healthcare. Intrauterine devices and subdermal implants require clinical certification, complex polymer fabrication, and physician distribution networks that construct durable barriers to entry. Bayer retains international sales forces and clinical support teams that distribute Mirena and related products across more than 100 countries.
Because the division exhibits high gross margins and predictable demand unaffected by economic downswings, the vehicle generates steady contractual dividends to Apollo and KKR without impinging upon the ongoing operating budget of the Bayer research pipeline. Bayer recorded group sales of €45.6 billion in 2025. The €1.37 billion revenue contributed by the contraceptives portfolio gave Apollo and KKR visible income coverage to anchor the €3 billion valuation without demanding operational concessions.
Apollo closed the transaction following receipt of regulatory approvals and satisfaction of customary antitrust closing conditions on September 16, 2026.
